IL-6 as a marker for NMOSD disease activity

Adi Haramati; Ariel Rechtman; Omri Zveik; Nitzan Haham; Livnat Brill; Adi Vaknin-Dembinsky

doi:10.1016/j.jneuroim.2022.577925

IL-6 as a marker for NMOSD disease activity

J Neuroimmunol. 2022 Sep 15:370:577925. doi: 10.1016/j.jneuroim.2022.577925. Epub 2022 Jul 2.

Authors

Adi Haramati¹, Ariel Rechtman², Omri Zveik², Nitzan Haham², Livnat Brill², Adi Vaknin-Dembinsky³

Affiliations

¹ Department of Neurology and Laboratory of Neuroimmunology and the Agnes-Ginges Center for Neurogenetics, Hadassah- Medical Center, Ein-Kerem, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel; Department of Military Medicine, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
² Department of Neurology and Laboratory of Neuroimmunology and the Agnes-Ginges Center for Neurogenetics, Hadassah- Medical Center, Ein-Kerem, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
³ Department of Neurology and Laboratory of Neuroimmunology and the Agnes-Ginges Center for Neurogenetics, Hadassah- Medical Center, Ein-Kerem, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel. Electronic address: adembinsky@gmail.com.

PMID: 35810527
DOI: 10.1016/j.jneuroim.2022.577925

Abstract

To date, there are no accepted soluble markers for disease activity and progression of neuromyelitis optica spectrum disorder (NMOSD). We aimed to evaluate longitudinal interleukin (IL)-6 levels in sera of NMOSD patients in correlation with disease activity and brain volume. We analyzed IL-6 serum levels of 26 NMOSD patients during relapse and remission. Significantly increased IL-6 levels were detected in patients with NMOSD during relapse. Furthermore, increased IL-6 levels correlated with relapse severity and brain atrophy. Our findings suggest that IL-6 serum level could serve as a biomarker for disease activity in NMOSD.

Keywords: Biomarker; Brain volume; Interleukin 6; Neuromyelitis Optica; Relapse.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Biomarkers
Humans
Interleukin-6 / analysis*
Neuromyelitis Optica* / diagnosis
Recurrence

Substances

Biomarkers
IL6 protein, human
Interleukin-6